SEEL - Seelos Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Seelos Therapeutics, Inc.

300 Park Avenue
12th Floor
New York, NY 10022
United States
646-998-6475
http://www.seelostherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. Raj Mehra Ph.D.Founder, Chairman, CEO, Pres & Interim CFO708.81kN/A1960
Anthony MarcianoHead of Corp. CommunicationsN/AN/AN/A
Gopal KrishnaHead of Manufacturing & Technical OperationsN/AN/AN/A
Tim WhitakerHead of R&DN/AN/AN/A
Jessica KardishHead of Clinical OperationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's disease or Lewy Body Dementia; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and orphan indications; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. The company was founded in 2016 and is headquartered in New York, New York.

Corporate Governance

Seelos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.